189 related articles for article (PubMed ID: 29674947)
1. Health and Social Problems Associated with Recent Novel Psychoactive Substance (NPS) Use Amongst Marginalised, Nightlife and Online Users in Six European Countries.
Van Hout MC; Benschop A; Bujalski M; Dąbrowska K; Demetrovics Z; Felvinczi K; Hearne E; Henriques S; Kaló Z; Kamphausen G; Korf D; Silva JP; Wieczorek Ł; Werse B
Int J Ment Health Addict; 2018; 16(2):480-495. PubMed ID: 29674947
[TBL] [Abstract][Full Text] [Related]
2. Negative consequences of novel psychoactive substances use among the Polish users.
Wieczorek Ł; Bujalski M; Dąbrowska K
Psychiatr Pol; 2021 Apr; 55(2):447-469. PubMed ID: 34365491
[TBL] [Abstract][Full Text] [Related]
3. Motives for using new psychoactive substances in three groups of Polish users: nightlife, marginalised and active on the In.
Wieczorek Ł; Dąbrowska K; Bujalski M
Psychiatr Pol; 2022 Jun; 56(3):453-470. PubMed ID: 36342979
[TBL] [Abstract][Full Text] [Related]
4. Why do people use new psychoactive substances? Development of a new measurement tool in six European countries.
Benschop A; Urbán R; Kapitány-Fövény M; Van Hout MC; Dąbrowska K; Felvinczi K; Hearne E; Henriques S; Kaló Z; Kamphausen G; Silva JP; Wieczorek Ł; Werse B; Bujalski M; Korf D; Demetrovics Z
J Psychopharmacol; 2020 Jun; 34(6):600-611. PubMed ID: 32043399
[TBL] [Abstract][Full Text] [Related]
5. New psychoactive substance use as a survival strategy in rural marginalised communities in Hungary.
Csák R; Szécsi J; Kassai S; Márványkövi F; Rácz J
Int J Drug Policy; 2020 Nov; 85():102639. PubMed ID: 31911024
[TBL] [Abstract][Full Text] [Related]
6. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
Napoletano S; Basile G; Lo Faro AF; Negro F
Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
[TBL] [Abstract][Full Text] [Related]
7. Novel psychoactive substances (NPS) - knowledge and expe riences of drug users from Hungary, Poland, the UK and the USA.
Pisarska A; Deluca P; Demetrovics Z; Moskalewicz J; ReDNet G
Neuropsychopharmacol Hung; 2019 Dec; 21(4):152-163. PubMed ID: 32015192
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users.
Sande M
Int J Drug Policy; 2016 Jan; 27():65-73. PubMed ID: 25908121
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
Gray R; Bressington D; Hughes E; Ivanecka A
J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
[TBL] [Abstract][Full Text] [Related]
10. Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances.
Deligianni E; Daniel OJ; Corkery JM; Schifano F; Lione LA
Br J Clin Pharmacol; 2020 Mar; 86(3):505-516. PubMed ID: 31495968
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of psychiatric inpatients diagnosed with mental and behavioral disorders caused by psychoactive substances (F11-19 block), with a focus on NPS and psychiatric co-morbidities.
Engelgardt P; Krzyżanowski M; Piotrowski P; Borkowska-Sztachańska M; Wasilewska A; Kowalkowski T
Int J Occup Med Environ Health; 2020 Mar; 33(2):125-136. PubMed ID: 31942874
[TBL] [Abstract][Full Text] [Related]
12. New/emerging psychoactive substances and associated psychopathological consequences.
Schifano F; Napoletano F; Chiappini S; Guirguis A; Corkery JM; Bonaccorso S; Ricciardi A; Scherbaum N; Vento A
Psychol Med; 2021 Jan; 51(1):30-42. PubMed ID: 31327332
[TBL] [Abstract][Full Text] [Related]
13. Motivations for new psychoactive substance use among regular psychostimulant users in Australia.
Sutherland R; Bruno R; Peacock A; Lenton S; Matthews A; Salom C; Dietze P; Butler K; Burns L; Barratt MJ
Int J Drug Policy; 2017 May; 43():23-32. PubMed ID: 28161577
[TBL] [Abstract][Full Text] [Related]
14. An international survey on the awareness, use, preference, and health perception of novel psychoactive substances (NPS).
Deligianni E; Corkery JM; Schifano F; Lione LA
Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28485125
[TBL] [Abstract][Full Text] [Related]
15. Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project.
Corazza O; Assi S; Simonato P; Corkery J; Bersani FS; Demetrovics Z; Stair J; Fergus S; Pezzolesi C; Pasinetti M; Deluca P; Drummond C; Davey Z; Blaszko U; Moskalewicz J; Mervo B; Furia LD; Farre M; Flesland L; Pisarska A; Shapiro H; Siemann H; Skutle A; Sferrazza E; Torrens M; Sambola F; van der Kreeft P; Scherbaum N; Schifano F
Hum Psychopharmacol; 2013 Jul; 28(4):317-23. PubMed ID: 23881879
[TBL] [Abstract][Full Text] [Related]
16. Correlates of new psychoactive substance use among a self-selected sample of nightclub attendees in the United States.
Palamar JJ; Barratt MJ; Ferris JA; Winstock AR
Am J Addict; 2016 Aug; 25(5):400-7. PubMed ID: 27419383
[TBL] [Abstract][Full Text] [Related]
17. Novel psychoactive drug use among younger adults involved in US nightlife scenes.
Kelly BC; Wells BE; Pawson M; Leclair A; Parsons JT; Golub SA
Drug Alcohol Rev; 2013 Nov; 32(6):588-93. PubMed ID: 23795887
[TBL] [Abstract][Full Text] [Related]
18. New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries.
Kurcevič E; Lines R
Harm Reduct J; 2020 Nov; 17(1):94. PubMed ID: 33256747
[TBL] [Abstract][Full Text] [Related]
19. New psychoactive substance use among regular psychostimulant users in Australia, 2010-2015.
Sutherland R; Peacock A; Whittaker E; Roxburgh A; Lenton S; Matthews A; Butler K; Nelson M; Burns L; Bruno R
Drug Alcohol Depend; 2016 Apr; 161():110-8. PubMed ID: 26880592
[TBL] [Abstract][Full Text] [Related]
20. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
